Cantor Fitzgerald assumed coverage of Anteris Technologies with an Overweight rating and $15 price target. Anteris is positioned to capture meaningful share of the $12.4B transcatheter aortic valve replacement market for treating aortic stenosis as its differentiated TAVR platform, DurAVR, advances towards commercialization, the analyst tells investors in a research note. DurVAR could disrupt the TAVR duopoly as it has targeted unmet clinical needs, the firm says.
